Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Simmons

Showing results (371-380 of 391) with videos related to

Pageof 40
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2021
No evidence for widespread island extinctions after Pleistocene hominin arrivalJulien Louys, Todd J Braje, Chun-Hsiang Chang, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2025
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsisRobert Silasi, Ravi S Keshari, Tomohiro Abe, et al.
Pediatric Diabetes|April 30, 2025
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up ResultsKellee M Miller, Colleen Bauza, Lauren G Kanapka, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Cancer Research|January 8, 2011
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.
Journal of Clinical Microbiology|April 4, 2000
Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzerG T Maine, R Stricker, M Schuler, et al.
The New England Journal of Medicine|March 9, 2012
Enzyme-replacement therapy in life-threatening hypophosphatasiaMichael P Whyte, Cheryl R Greenberg, Nada J Salman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 20, 2023
Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working GroupEric Rush, Maria Luisa Brandi, Aliya Khan, et al.
Pageof 40

Showing results (371-380 of 391) with videos related to

Sort By:
Pageof 40
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 4, 2021
No evidence for widespread island extinctions after Pleistocene hominin arrivalJulien Louys, Todd J Braje, Chun-Hsiang Chang, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2025
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsisRobert Silasi, Ravi S Keshari, Tomohiro Abe, et al.
Pediatric Diabetes|April 30, 2025
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up ResultsKellee M Miller, Colleen Bauza, Lauren G Kanapka, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Cancer Research|January 8, 2011
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.
Journal of Clinical Microbiology|April 4, 2000
Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzerG T Maine, R Stricker, M Schuler, et al.
The New England Journal of Medicine|March 9, 2012
Enzyme-replacement therapy in life-threatening hypophosphatasiaMichael P Whyte, Cheryl R Greenberg, Nada J Salman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 20, 2023
Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working GroupEric Rush, Maria Luisa Brandi, Aliya Khan, et al.
Pageof 40